Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Colorectal Cancer Drugs Market From 2025 to 2029?

In recent times, there has been stable growth in the market size of colorectal cancer medications. It is projected to rise from $20.72 billion in 2024 to $21.72 billion in 2025, experiencing a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period is due to the amalgamation of multimodal approaches, the implementation of chemotherapy, advancements in surgical methods, the introduction of targeted therapies, along with the execution of clinical trials and research.

In the forthcoming years, we predict a robust expansion in the colorectal cancer drugs market. The market size will reach “$27.01 billion by 2029, with a compound annual growth rate (CAGR) of 5.6%. The predicted expansion during the forecast period is due to the increase in personalized treatments, shift towards patient-centric care systems, expansion of targeted therapies, and the uptake of combination therapies, in addition to accelerated regulatory measures. Key trends expected during the forecast timeframe include immunotherapy improvements, developments in precision medicine, combination treatments, advancements in biomarker research and utilization, along with innovation in clinical trials.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2590&type=smp

What Elements Are Contributing To Growth In The Colorectal Cancer Drugs Market?

The escalating need for customized medications is anticipated to stimulate the expansion of the colorectal cancer drugs market in the future. Customized medicine, alternatively known as precision medicine, is a healthcare and medical treatment strategy that factors in the distinct genetic, environmental, and lifestyle differences of patients. This type of medicine is revolutionizing the way colorectal cancer is treated, providing more personalized and effective care to patients. It’s expected to furthermore bolster the growth of the colorectal cancer drug market as the focus on research and drug development becomes more tailored towards distinct genetic and molecular profiles. For example, the Personalized Medicine Coalition, a non-profit organization based in the US, reported in February 2024 that the FDA approved 16 new customized therapies for patients with rare diseases in 2023. This represents a significant increase from the six that were approved in 2022. Thus, the burgeoning demand for personalized medicine is fuelling the growth of the colorectal cancer drugs market.

The colorectal cancer drugs market covered in this report is segmented –

1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, BRAF Or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators

2) By Class: Immunotherapy, Chemotherapy, Other Classes

3) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab, Ramucirumab, Other VEGF Inhibitors

2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab, Panitumumab, Other EGFR Inhibitors

3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab, Nivolumab, Other PD1 Or PDL1 Inhibitors

4) By BRAF Or MEK Inhibitors: Vemurafenib, Encorafenib, Trametinib, Other BRAF Or MEK Inhibitors

5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib, Sorafenib, Other TKI Inhibitors

6) By Immunomodulators: Checkpoint Inhibitors, Other Immunomodulating Agents

What Are The Leading Trends And Opportunities In The Colorectal Cancer Drugs Sector?

The life expectancy of patients suffering from metastatic Colorectal cancer has already begun to improve, thanks to targeted therapies, in contrast to therapies only using chemotherapy. These targeted therapies encompass a range of approaches, such as hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Their growing significance lies in their precision in targeting cancer cells, thereby reducing toxicity to non-target cells. Two examples of such targeted therapies are Opdivo and Keytruda.

Who Are The Key Contributors To Growth In The Colorectal Cancer Drugs Market?

Major companies operating in the colorectal cancer drugs market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Taiho Oncology Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Which Region Is Projected To Lead The Colorectal Cancer Drugs Market By 2025?

North America was the largest region in the colorectal cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2590&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model